A REVIEW OF THE CLINICAL TRANSLATION OF NANOEMULSIONS, DOXIL AND LIPID NANOPARTICLES
Main Article Content
Authors
Xianghua Yang
School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, P. R. China
These authors contributed equally
Shiqi Liu
School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, P. R. China
These authors contributed equally
Yixiang Su
School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, P. R. China
These authors contributed equally
Haoxiang Yang
School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, P. R. China
Didar Baimanov1
School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, P. R. China
Abstract
Nanomedicine has reshaped the clinical use of therapeutics by changing how payloads are formulated, protected, distributed and released. Yet despite decades of innovation, only a limited number of nanocarrier platforms have achieved sustained clinical impact. Here, we examine nanoemulsions, Doxil and lipid nanoparticles (LNPs) as three clinically validated platforms spanning increasing levels of carrier dependence. Nanoemulsions primarily solve formulation and administration constraints. Doxil reprograms the pharmacokinetics and toxicity of an established drug. LNPs enable nucleic acid therapeutics whose clinical activity depends on carrier-mediated protection, delivery and intracellular release. This reveals a central principle of translational nanomedicine: clinical value emerges when carrier function addresses an indispensable therapeutic need, rather than when nanoscale complexity is pursued as an end in itself. We further discuss how biological identity, tissue transport, cellular processing, payload release and manufacturability determine whether this functional advantage is retained in patients. Framing nanomedicines according to therapeutic dependence on the carrier provides a clinically grounded basis for understanding past successes and guiding the design of the next generation of translatable nanotherapeutics.
Keywords
nanomedicine, nanoemulsions, Doxil and lipid nanoparticles, clinically approved drugs
Article Details
References
Abdel-Mageed H.M., AbuelEzz N.Z., Radwan R.A., Mohamed S.A. Nanoparticles in nanomedicine: a comprehensive updated review on current status, challenges and emerging opportunities. // J. Microencapsulation. – 2021. – № 38(6). – P. 414–436.
Elzoghby A.O., Samy W.M., Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. // J. Control. Release. – 2012. – № 157(2). – P. 168–182.
George S.C., Thomas S. Transport phenomena through polymeric systems. // Prog. Polym. Sci. – 2001. – № 26(6). – P. 985–1017.
Ali A., Zafar H., Zia M., ul Haq I., Phull A.R., Ali J.S., Hussain A. Synthesis, characterization, applications, and challenges of iron oxide nanoparticles. // Nanotechnol. Sci. Appl. – 2016. – № 9. – P. 49–67.
Naseema A., Kovooru L., Behera A.K., Kumar K.P., Srivastava P. A critical review of synthesis procedures, applications and future potential of nanoemulsions. // Adv. Colloid Interface Sci. – 2021. – № 287. – Art. 102318.
Ozogul Y., Karsli G.T., Durmuş M., Yazgan H., Oztop H.M., McClements D.J., Ozogul F. Recent developments in industrial applications of nanoemulsions. // Adv. Colloid Interface Sci. – 2022. – № 304. – Art. 102685.
Skelton R., Roach A., Prudhomme L.E., Cen Feng J.Y.C., Gaikwad P., Williams R.M. Formulation of lipid-free polymeric mesoscale nanoparticles encapsulating mRNA: polymer nanoparticle mRNA formulation. // Pharm. Res. – 2022. – № 39(11). – P. 2699–2707.
Ganta S., Talekar M., Singh A., Coleman T.P., Amiji M.M. Nanoemulsions in translational research—opportunities and challenges in targeted cancer therapy. // AAPS PharmSciTech. – 2014. – № 15(3). – P. 694–708.
Zhao Y.-Q., Li L.-J., Zhou E.-F., Wang J.-Y., Wang Y., Guo L.-M., Zhang X.-X. Lipid-based nanocarrier systems for drug delivery: advances and applications. // Pharm. Fronts. – 2022. – № 4(2). – P. e43–e60.
Piper S.N., Schade I., Beschmann R.B., Maleck W.H., Boldt J., Röhm K.D. Hepatocellular integrity after parenteral nutrition: comparison of a fish-oil-containing lipid emulsion with an olive-soybean oil-based lipid emulsion. // Eur. J. Anaesthesiol. – 2009. – № 26(12). – P. 1076–1082.
Lu B., Wei L., Shi G., Du J. Nanotherapeutics for alleviating anesthesia-associated complications. // Adv. Sci. – 2024. – № 11(15). – Art. e2308241.
Vaneev A., Tikhomirova V., Chesnokova N., Popova E., Beznos O., Kost O., Klyachko N. Nanotechnology for topical drug delivery to the anterior segment of the eye. // Int. J. Mol. Sci. – 2021. – № 22(22). – Art. 12368.
Petkar K.C., Patil S.M., Chavhan S.S., Kaneko K., Sawant K.K., Kunda N.K., Saleem I.Y. An overview of nanocarrier-based adjuvants for vaccine delivery. // Pharmaceutics. – 2021. – № 13(4). – Art. 455.
Xu L., Chen R., Wang X., Liu D., Liu Y., Zhao C.X. DNA barcoding-enabled tracking of lipid nanoparticles: drug-loading-dependent biodistribution and tumor microenvironment targeting. // Adv. Healthc. Mater. – 2025. – № 14(24). – Art. 2501914.
Chougule M.B., Patel A.R., Jackson T., Singh M. Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. // PLoS One. – 2011. – № 6(3). – Art. e17733.
Ranson M.R., Cheeseman S., White S., Margison J. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. // Crit. Rev. Oncol. Hematol. – 2001. – № 37(2). – P. 115–120.
Inglut C.T., Sorrin A.J., Kuruppu T., Vig S., Cicalo J., Ahmad H., Huang H.-C. Immunological and toxicological considerations for the design of liposomes. // Nanomaterials. – 2020. – № 10(2). – Art. 190.
Gabizon A.A., Gabizon-Peretz S., Modaresahmadi S., La-Beck N.M. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. // BMJ Oncol. – 2025. – № 4(1). – Art. e000573.
Guo Q., Wang S., Xu R., Tang Y., Xia X. Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform. // RSC Adv. – 2024. – № 14(15). – P. 10608–10637.
Spadea A., Jackman M., Cui L., Pereira S., Lawrence M.J., Campbell R.A., Ashford M. Nucleic acid-loaded lipid nanoparticle interactions with model endosomal membranes. // ACS Appl. Mater. Interfaces. – 2022. – № 14(26). – P. 30371–30384.
Zwolsman R., Darwish Y.B., Kluza E., van Der Meel R. Engineering lipid nanoparticles for mRNA immunotherapy. // Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. – 2025. – № 17(2). – Art. e70007.
Hu B., Zhong L., Weng Y., Peng L., Huang Y., Zhao Y., Liang X.-J. Therapeutic siRNA: state of the art. // Signal Transduct. Target. Ther. – 2020. – № 5(1). – Art. 101.
Zhang G., Tang T., Chen Y., Huang X., Liang T. mRNA vaccines in disease prevention and treatment. // Signal Transduct. Target. Ther. – 2023. – № 8(1). – Art. 365.
Adams D., Gonzalez-Duarte A., O'Riordan W.D., Yang C.C., Ueda M., Kristen A.V., Tournev I., Schmidt H.H., Coelho T., Berk J.L., et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. // N. Engl. J. Med. – 2018. – № 379(1). – P. 11–21.
Baimanov D., Wang J., Chen C., Wang L. Receptor discovery for nanomaterial soft and hard coronas via a biosensor-based fishing strategy. // Nat. Protoc. – 2026. – № 1–46.
Kim Y., Park J., Choi J., Kim M., Seo G., Kim J., Park J.-A., Lim K.S., Ha S.-J., Kim H.-O. Physiological barriers to nucleic acid therapeutics and engineering strategies for lipid nanoparticle design, optimization, and clinical translation. // Pharmaceutics. – 2025. – № 17(10). – Art. 1309.
Wu Q., Yao X., Duan X., Chen X., Zhang J. Nanomedicine reimagined: translational strategies for precision tumor theranostics. // Adv. Mater. – 2026. – № 38(8). – Art. e10293.
Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. // Cancer Invest. – 2001. – № 19(4). – P. 424–436.
Tomsits E., Pataki M., Tölgyesi A., Fekete G., Rischak K., Szollár L. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium‐chain triglycerides, olive oil, and fish oil: a randomised, double‐blind clinical trial in premature infants requiring parenteral nutrition. // J. Pediatr. Gastroenterol. Nutr. – 2010. – № 51(4). – P. 514–521.
Lallemand F., Daull P., Benita S., Buggage R., Garrigue J.-S. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. // J. Drug Deliv. – 2012. – № 2012(1). – Art. 604204.
Bisso S., Leroux J.-C. Nanopharmaceuticals: A focus on their clinical translatability. // Int. J. Pharm. – 2020. – № 578. – Art. 119098.
Ottoboni T., Keller M.R., Cravets M., Clendeninn N., Quart B. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. // Drug Des. Devel. Ther. – 2018. – № 12. – P. 429–435.
O'Hagan D.T., Ott G.S., Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. // Mol. Med. Today. – 1997. – № 3(2). – P. 69–75.
Edmunds C.E., Brody R.A., Parrott J.S., Stankorb S.M., Heyland D.K. The effects of different IV fat emulsions on clinical outcomes in critically ill patients. // Crit. Care Med. – 2014. – № 42(5). – P. 1168–1177.
Freeman D., Grant D., Levy G., Rochon J., Wong P.-Y., Altraif I., Asfar S. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. // Ther. Drug Monit. – 1995. – № 17(3). – P. 213–216.
Erkko P., Granlund H., Nuutinen M., Reitamo S. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis. // Br. J. Dermatol. – 1997. – № 136(1). – P. 82–88.
Dranitsaris G., Moezi M., Dobson K., Phelan R., Blau S. A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. // Support Care Cancer. – 2022. – № 30(8). – P. 6649–6658.
Donoghue V., Schleicher G., Spruyt M., Malan L., Nel D., Calder P., Blaauw R. Four-oil intravenous lipid emulsion effect on plasma fatty acid composition, inflammatory markers and clinical outcomes in acutely ill patients: a randomised control trial (foil fact). // Clin. Nutr. – 2019. – № 38(6). – P. 2583–2591.
Goulet O.J., Cai W., Seo J.M. Lipid emulsion use in pediatric patients requiring long-term parenteral nutrition. // JPEN J. Parenter. Enteral Nutr. – 2020. – № 44. – P. S55–S67.
Preeti, Sambhakar S., Malik R., Bhatia S., Al Harrasi A., Rani C., Saharan R., Kumar S., Geeta, Sehrawat R. Nanoemulsion: an emerging novel technology for improving the bioavailability of drugs. // Scientifica. – 2023. – № 2023(1). – Art. 6640103.
Lee J., Choi M.-K., Song I.-S. Recent advances in doxorubicin formulation to enhance pharmacokinetics and tumor targeting. // Pharmaceuticals. – 2023. – № 16(6). – Art. 802.
Sohail M., Sun Z., Li Y., Gu X., Xu H. Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. // Expert Rev. Anticancer Ther. – 2021. – № 21(12). – P. 1385–1398.
Udhrain A., Skubitz K.M., Northfelt D.W. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma. // Int. J. Nanomedicine. – 2007. – № 2(3). – P. 345–352.
Marchal S., Hor A.E., Millard M., Gillon V., Bezdetnaya L. Anticancer drug delivery: an update on clinically applied nanotherapeutics. // Drugs. – 2015. – № 75(14). – P. 1601–1611.
Uzakova A.B., Yergaliyeva E.M., Yerlanuly A., Mukatayeva Z.S. A systematic review of advanced drug delivery systems: engineering strategies, barrier penetration, and clinical progress (2016–April 2025). // Pharmaceutics. – 2025. – № 18(1). – Art. 11.
Mohamed M., Abu Lila A.S., Shimizu T., Alaaeldin E., Hussein A., Sarhan H.A., Szebeni J., Ishida T. PEGylated liposomes: immunological responses. // Sci. Technol. Adv. Mater. – 2019. – № 20(1). – P. 710–724.
Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. // Clin. Pharmacokinet. – 2003. – № 42(5). – P. 419–436.
Anchordoquy T., Artzi N., Balyasnikova I.V., Barenholz Y., La-Beck N.M., Brenner J.S., Chan W.C.W., Decuzzi P., Exner A.A., Gabizon A. Mechanisms and barriers in nanomedicine: Progress in the field and future directions. // ACS Nano. – 2024. – № 18(22). – Art. 17.
Solomon R., Gabizon A.A. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. // Clin. Lymphoma Myeloma. – 2008. – № 8(1). – P. 21–32.
Franco Y.L., Vaidya T.R., Ait-Oudhia S. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. // Breast Cancer. – 2018. – № 10. – P. 131–141.
Youden B., Jiang R., Carrier A.J., Servos M.R., Zhang X. A nanomedicine structure–activity framework for research, development, and regulation of future cancer therapies. // ACS Nano. – 2022. – № 16(11). – P. 17497–17551.
Gonda A., Zhao N., Shah J.V., Calvelli H.R., Kantamneni H., Francis N.L., Ganapathy V. Engineering tumor-targeting nanoparticles as vehicles for precision nanomedicine. // MedOne. – 2019. – № 4. – Art. e190021.
Tejada-Berges T., Granai C., Gordinier M., Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. // Expert Rev. Anticancer Ther. – 2002. – № 2(2). – P. 143–150.
Duggan S.T., Keating G.M. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma. // Drugs. – 2011. – № 71(18). – P. 2531–2558.
Plosker G.L. Pegylated liposomal doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. // Drugs. – 2008. – № 68(17). – P. 2535–2551.
Yan J., Zhang H., Li G., Su J., Wei Y., Xu C. Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design. // Acta Pharm. Sin. B. – 2024. – № 14(2). – P. 579–601.
Gu Q., Xue H., Liu Z., Rao J., Zeng L., Zhang C., Lei L., Shi L. Developing biomaterial-based mRNA delivery system for lung disease treatment. // Adv. Sci. – 2025. – № 12(34). – Art. e05413.
Ko K.H., Lee S.H., Choi Y.H., Kang S.M., Yang H.S., Lee S.M., Jo E.B., Bae H.S., Hong S.B., Kim D.H. Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses. // NPJ Vaccines. – 2025. – № 11(1). – P. 1–14.
Suri K., Pfeifer L., Cvet D., Li A., Mccoy M., Singh A., Amiji M.M. Oral delivery of stabilized lipid nanoparticles for nucleic acid therapeutics. // Drug Deliv. Transl. Res. – 2025. – № 15(5). – P. 1755–1769.
Basha G., Novobrantseva T.I., Rosin N., Tam Y.Y.C., Hafez I.M., Wong M.K., Sugo T., Ruda V.M., Qin J., Klebanov B. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. // Mol. Ther. – 2011. – № 19(12). – P. 2186–2200.
Kumar V., Qin J., Jiang Y., Duncan R.G., Kasperkovitz P.V. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. // Mol. Ther. Nucleic Acids. – 2014. – № 3(11). – Art. e210.
Shi Y., Huang J., Liu Y., Liu J., Guo X., Li J., Gong L., Zhou X., Cheng G., Qiu Y., et al. Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses. // Sci. Adv. – 2022. – № 8(47). – Art. eabo1827.
Peng K., Zhao X., Fu Y.X., Liang Y. Eliciting antitumor immunity via therapeutic cancer vaccines. // Cell. Mol. Immunol. – 2025. – № 22(8). – P. 840–868.
Wheeler J., Palmer L., Ossanlou M., MacLachlan I., Graham R., Zhang Y., Hope M., Scherrer P., Cullis P. Stabilized plasmid-lipid particles: construction and characterization. // Gene Ther. – 1999. – № 6(2). – P. 271–281.
Semple S.C., Klimuk S.K., Harasym T.O., Dos Santos N., Ansell S.M., Wong K.F., Maurer N., Stark H., Cullis P.R., Hope M.J. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. // Biochim. Biophys. Acta Biomembr. – 2001. – № 1510(1–2). – P. 152–166.
Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. // Nat. Biotechnol. – 2005. – № 23(8). – P. 1002–1007.
Lin Y., Cheng Q., Wei T. Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond. // Biophys. Rep. – 2023. – № 9(5). – P. 255–278.
Kishore R., Magadum A. Cell-specific mRNA therapeutics for cardiovascular diseases and regeneration. // J. Cardiovasc. Dev. Dis. – 2024. – № 11(2). – Art. 38392252.
Hou X., Zaks T., Langer R., Dong Y. Lipid nanoparticles for mRNA delivery. // Nat. Rev. Mater. – 2021. – № 6(12). – P. 1078–1094.
Prazeres P.H.D.M., Ferreira H., Costa P.A.C., Silva W.D., Alves M.T., Padilla M., Thatte A., Santos A.K., Lobo A.O., Sabino A. Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells. // Int. J. Nanomedicine. – 2023. – № 18. – P. 5891–5904.
Khare P., Edgecomb S.X., Hamadani C.M., Conway J.F., Tanner E.E.L., Manickam D.S. Ionic liquid-coated lipid nanoparticles increase siRNA uptake into CNS targets. // Nanoscale Adv. – 2024. – № 6(7). – P. 1853–1873.
Pardi N., Hogan M.J., Pelc R.S., Muramatsu H., Andersen H., DeMaso C.R., Dowd K.A., Sutherland L.L., Scearce R.M., Parks R. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. // Nature. – 2017. – № 543(7644). – P. 248–251.
Sahin U., Derhovanessian E., Miller M., Kloke B.-P., Simon P., Löwer M., Bukur V., Tadmor A.D., Luxemburger U., Schrörs B. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. // Nature. – 2017. – № 547(7662). – P. 222–226.
Ramaswamy S., Tonnu N., Tachikawa K., Limphong P., Vega J.B., Karmali P.P., Chivukula P., Verma I.M. Systemic delivery of factor IX messenger RNA for protein replacement therapy. // Proc. Natl. Acad. Sci. U. S. A. – 2017. – № 114(10). – P. E1941–E1950.
Gillmore J.D., Gane E., Taubel J., Kao J., Fontana M., Maitland M.L., Seitzer J., O’Connell D., Walsh K.R., Wood K. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. // N. Engl. J. Med. – 2021. – № 385(6). – P. 493–502.
Gao M., Zhang Q., Feng X.H., Liu J. Synthetic modified messenger RNA for therapeutic applications. // Acta Biomater. – 2021. – № 131. – P. 1–15.
Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. // Proc. Natl. Acad. Sci. U. S. A. – 1987. – № 84(21). – P. 7413–7417.
Akinc A., Maier M.A., Manoharan M., Fitzgerald K., Jayaraman M., Barros S., Ansell S., Du X., Hope M.J., Madden T.D. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. // Nat. Nanotechnol. – 2019. – № 14(12). – P. 1084–1087.
Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. // N. Engl. J. Med. – 2020. – № 383(27). – P. 2603–2615.
Das P., Panda J.R., Patro C.N., Sahu B., Patnaik S.S. A comprehensive review of nanoemulsion applications and their recent advancements. // Curr. Nanosci. – 2023. – № 8(3). – P. 209–223.
Kong W., Chen W., Hui J., Qiu L. Emerging nanocarriers designed for the enhanced delivery of doxorubicin. // Nanomedicine. – 2025. – № 20(14). – P. 1729–1744.
Villarreal-Gómez L.J., Serrano-Medina A., José Torres-Martínez E., Lizeth Perez-González G., Manuel Cornejo-Bravo J. Polymeric advanced delivery systems for antineoplasic drugs: doxorubicin and 5-fluorouracil. // e-Polymers. – 2018. – № 18(4). – P. 359–372.
Drummond D.C., Noble C.O., Hayes M.E., Park J.W., Kirpotin D.B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. // J. Pharm. Sci. – 2008. – № 97(11). – P. 4696–4740.
Cheng Q., Wei T., Farbiak L., Johnson L.T., Dilliard S.A., Siegwart D.J. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. // Nat. Nanotechnol. – 2020. – № 15(4). – P. 313–320.
Gilleron J., Querbes W., Zeigerer A., Borodovsky A., Marsico G., Schubert U., Manygoats K., Seifert S., Andree C., Stöter M. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. // Nat. Biotechnol. – 2013. – № 31(7). – P. 638–646.
Ishida T., Atobe K., Wang X., Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. // J. Control. Release. – 2006. – № 115(3). – P. 251–258.
Ndeupen S., Qin Z., Jacobsen S., Bouteau A., Estanbouli H., Igyártó B.Z. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. // iScience. – 2021. – № 24(12). – Art. 103479.
Muramatsu H., Lam K., Bajusz C., Laczkó D., Karikó K., Schreiner P., Martin A., Lutwyche P., Heyes J., Pardi N. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. // Mol. Ther. – 2022. – № 30(5). – P. 1941–1951.
Shankar R., Upadhyay P.K., Kumar M. Nanoemulsions a delivery system in the making for tumor targeting therapeutics: evaluation and characterization to meet clinical challenges. // Curr. Pharm. Biotechnol. – 2025. – № 26(7). – P. 1069–1087.
Kokkinopoulou M., Simon J., Landfester K., Mailänder V., Lieberwirth I. Visualization of the protein corona: towards a biomolecular understanding of nanoparticle-cell-interactions. // Nanoscale. – 2017. – № 9(25). – P. 8858–8870.
Navarro-Marchal S.A., Martín-Contreras M., Castro-Santiago D., del Castillo-Santaella T., Graván P., Jódar-Reyes A.B., Marchal J.A., Peula-García J.M. Effect of the protein corona formation on antibody functionalized liquid lipid nanocarriers. // Int. J. Mol. Sci. – 2023. – № 24(23). – Art. 16759.
Nel A.E., Mädler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., Klaessig F., Castranova V., Thompson M. Understanding biophysicochemical interactions at the nano–bio interface. // Nat. Mater. – 2009. – № 8(7). – P. 543–557.
Sanchez-Moreno P., Buzón P., Boulaiz H., Peula-García J., Ortega-Vinuesa J., Luque I., Salvati A., Marchal J. Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules. // Biomaterials. – 2015. – № 61. – P. 266–278.
Patel S.K. Macrophage COX-2 as a Target for Imaging and Therapy of Inflammatory Diseases Using Theranostic Nanoemulsions. // Ph.D. Dissertation. – Duquesne University, 2015.
Izadiyan Z., Webster T.J., Kia P., Kalantari K., Misran M., Rasouli E., Maghareh Esfahan Z., Shameli K. Nanoemulsions based therapeutic strategies: enhancing targeted drug delivery against breast cancer cells. // Int. J. Nanomedicine. – 2025. – № 20. – P. 6133–6162.
Jusril N.A., Abu Bakar S.I., Khalil K.A., Md Saad W.M., Wen N.K., Adenan M.I. Development and optimization of nanoemulsion from ethanolic extract of Centella asiatica (NanoSECA) using D‐optimal mixture design to improve blood‐brain barrier permeability. // Evid. Based Complement. Alternat. Med. – 2022. – № 2022(1). – Art. 3483511.
Li X., Tang C., Ye H., Fang C. Injectable hydrogel-encapsulating pickering emulsion for overcoming lenvatinib-resistant hepatocellular carcinoma via cuproptosis induction and stemness inhibition. // Polymers. – 2024. – № 16(17). – Art. 2418.
Rai V.K., Mishra N., Yadav K.S., Yadav N.P. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: Formulation development, stability issues, basic considerations and applications. // J. Control. Release. – 2018. – № 270. – P. 203–225.
Liu M., Chu Y., Liu H., Su Y., Zhang Q., Jiao J., Liu M., Ding J., Liu M., Hu Y. Accelerated blood clearance of nanoemulsions modified with PEG-cholesterol and PEG-phospholipid derivatives in rats: the effect of PEG-lipid linkages and PEG molecular weights. // Mol. Pharm. – 2019. – № 17(4). – P. 1059–1070.
Gupta V., Kumar D., Gupta S., Tanwar R., Jaiswal N.K., Islam M.M., Singh S., Choudhary N., Gowri S., Webster T.J. Nanotechnology-driven cancer therapies for precision oncology: advances and clinical outlook. // Int. J. Nanomedicine. – 2026. – № 21. – Art. 568254.
Meng H., Xue M., Xia T., Ji Z., Tarn D.Y., Zink J.I., Nel A.E. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. // ACS Nano. – 2011. – № 5(5). – P. 4131–4144.
Gramolelli S., Ojala P.M. Kaposi's sarcoma herpesvirus-induced endothelial cell reprogramming supports viral persistence and contributes to Kaposi's sarcoma tumorigenesis. // Curr. Opin. Virol. – 2017. – № 26. – P. 156–162.
Sanna V., Pala N., Sechi M. Targeted therapy using nanotechnology: focus on cancer. // Int. J. Nanomedicine. – 2014. – № 9. – P. 467–483.
Omidi Y., Barar J. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. // BioImpacts. – 2014. – № 4(2). – Art. 55.
Shin D., Choi J., Park B., Kim S.H., Shim M.K. Factors governing tumor penetration of nanomedicines: intrinsic and extrinsic determinants. // Nanoscale. – 2026. – № 18(5). – P. 2363–2381.
Li Y., Xu X., Hao T., Mao X., Guo P., Zhu X., Jin W., Geng H., Li F., Hu X. Amphiphilic zwitterionic polymers induce liposome morphogenesis into nanodiscs for deep glioblastoma infiltration. // Angew. Chem. Int. Ed. – 2026. – № 65(21). – Art. e2167334.
Baimanov D., Wang J., Liu Y., Zheng P., Yu S., Liu F., Wang J., Boraschi D., Zhao Y., Chen C. Identification of cell receptors responsible for recognition and binding of lipid nanoparticles. // J. Am. Chem. Soc. – 2025. – № 147(9). – P. 7604–7616.
Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. // Crit. Rev. Ther. Drug Carrier Syst. – 2001. – № 18(6). – P. 567–606.
Merrell D.S., Falkow S. Frontal and stealth attack strategies in microbial pathogenesis. // Nature. – 2004. – № 430(6996). – P. 250–256.
Ibrahim M., Abuwatfa W.H., Awad N.S., Sabouni R., Husseini G.A. Encapsulation, release, and cytotoxicity of doxorubicin loaded in liposomes, micelles, and metal-organic frameworks: a review. // Pharmaceutics. – 2022. – № 14(2). – Art. 254.
Yokomichi N., Nagasawa T., Coler-Reilly A., Suzuki H., Kubota Y., Yoshioka R., Tozawa A., Suzuki N., Yamaguchi Y. Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. // Hum. Cell. – 2013. – № 26(1). – P. 8–18.
Ferrari M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. // Trends Biotechnol. – 2010. – № 28(4). – P. 181–188.
Horacio C., Kanjiro M., Kensuke O., Kazunori K. Block Copolymer Micelles in Nanomedicine Applications. // Chem. Rev. – 2018. – № 118(14). – P. 6844–6892.
Sun D., Zhou S., Gao W. What went wrong with anticancer nanomedicine design and how to make it right. // ACS Nano. – 2020. – № 14(10). – P. 12281–12290.
Wei P.S., Thota N., John G., Chang E., Lee S., Wang Y., Ma Z., Tsai Y.H., Mei K.C. Enhancing RNA-lipid nanoparticle delivery: organ- and cell-specificity and barcoding strategies. // J. Control. Release. – 2024. – № 375. – P. 366–388.
Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., Jayaraman M., Rajeev K.G., Cantley W.L., Dorkin J.R. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. // Mol. Ther. – 2010. – № 18(7). – P. 1357–1364.
Haghighi E., Abolmaali S.S., Dehshahri A., Mousavi Shaegh S.A., Azarpira N., Tamaddon A.M. Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach. // J. Nanobiotechnology. – 2024. – № 22. – Art. 710.
Vasir J.K., Labhasetwar V. Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. // Biomaterials. – 2008. – № 29(31). – P. 4244–4252.
Mohite P., Yadav V., Pandhare R., Maitra S., Saleh F.M., Saleem R.M., Al-Malky H.S., Kumarasamy V., Subramaniyan V., Abdel-Daim M.M. Revolutionizing cancer treatment: unleashing the power of viral vaccines, monoclonal antibodies, and proteolysis-targeting chimeras in the new era of immunotherapy. // ACS Omega. – 2024. – № 9(7). – P. 7277–7295.
Lee Y., Jeong M., Park J., Jung H., Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. // Exp. Mol. Med. – 2023. – № 55(10). – P. 2085–2096.
Bae Y., Lee H., Lee J.H., Yeo S., Mok H. Histidine decapeptide-incorporating lipid nanoparticles with low ionizable lipids proportion for efficient small interfering RNA delivery. // Macromol. Biosci. – 2025. – № 25(9). – Art. e70005.
Zhang Y.Q., Guo R.R., Chen Y.H., Li T.C., Du W.Z., Xiang R.W., Guan J.B., Li Y.P., Huang Y.Y., Yu Z.Q. Ionizable drug delivery systems for efficient and selective gene therapy. // Mil. Med. Res. – 2023. – № 10(1). – Art. 9.
Lee K., Aviles Vargas A., Bottino R., Wang Y. Islet Transplantation: Microencapsulation, Nanoencapsulation, and Hypoimmune Engineering. // WIREs Nanomed. Nanobiotechnol. – 2025. – № 17(3). – Art. e70016.
Safford H.C., Swingle K.L., Geisler H.C., Hamilton A.G., Thatte A.S., Ghalsasi A.A., Billingsley M.M., Alameh M.G., Weissman D., Mitchell M.J. Orthogonal design of experiments for engineering of lipid nanoparticles for mRNA delivery to the placenta. // Small. – 2024. – № 20(41). – Art. 2303568.
Maeki M., Uno S., Niwa A., Okada Y., Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. // J. Control. Release. – 2022. – № 344. – P. 80–96.
Nomani A., Saraswat A., Brown H., Kuo C.T., Duong H.T.T., Wu J., Zhang Y., Fu Y., Moon Y., Wahidi S. Identifying key factors affecting mRNA-lipid nanoparticles drug product formulation stability. // Nanomaterials. – 2026. – № 16(4). – Art. 268.
Chang T., Zheng Y., Jiang M., Jia S., Bai J., Zheng Z., Li S., Guo J., Wang Y., Wang Y. Peptide codes for organ-selective mRNA delivery. // Nat. Mater. – 2026. – № 25(1). – P. 146–159.
Cullis P., Felgner P. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. // Nat. Rev. Drug Discov. – 2024. – № 23(9). – P. 709–722.
Kim S., Park C., Lee Y., Lee K., Lee H., Lee K. Inflammatory and immune-mediated toxicity of lipid nanoparticles. // Biomed. Pharmacother. – 2026. – № 199. – Art. 119385.
Meulewaeter S., Nuytten G., Cheng M.H.Y., Smedt S.C.D., Cullis P.R., Beer T.D., Lentacker I., Verbeke R. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. // J. Control. Release. – 2023. – № 357. – Art. 12.
Wang X., Xu L., Lan Z., Hui Y., Liu Y., Yang G., Zhao C.X. Advances in the development of lipid nanoparticles for mRNA delivery. // Small Struct. – 2026. – № 7(2). – Art. e202500568.
Joyce P., Allen C.J., Alonso M.J., Ashford M., Bradbury M.S., Germain M., Kavallaris M., Langer R., Lammers T., Peracchia M.T. A translational framework to DELIVER nanomedicines to the clinic. // Nat. Nanotechnol. – 2024. – № 19(11). – P. 1597–1611.
Mitchell M.J., Billingsley M.M., Haley R.M., Wechsler M.E., Peppas N.A., Langer R. Engineering precision nanoparticles for drug delivery. // Nat. Rev. Drug Discov. – 2021. – № 20(2). – P. 101–124.